Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report

• DOI: 10.1111/1759-7714.13983
• Publication Date: 2021-05-08T22:57:50Z
• Authors: Kunyan Sun; Ligong Nie; Lin Nong; Yuan Cheng
• Keywords: Alectinib; ALK inhibitor; Ceritinib; Receptor Protein-Tyrosine Kinases

Abstract Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset non‐small cell lung cancer (NSCLC). The rapid progression ALK inhibitors has significantly prolonged the progression‐free survival patients with gene‐sensitive mutations. However, response rare to tyrosine remains unknown. Here, we report case striatin (STRN)‐ALK‐positive NSCLC showing primary resistance first‐line therapy alectinib and limited clinical activity crizotinib in alectinib‐resistant setting.